Acadia Pharmaceuticals Announces Change in Research and Development Leadership

Rhea-AI Summary

Acadia Pharmaceuticals Inc. (ACAD) announces the departure of Dr. Doug Williamson, the Executive Vice President, Head of Research and Development, who will be leaving the company to pursue other opportunities. Dr. Williamson joined Acadia in January 2023 and will continue in his role during a transitional period. The company has initiated a search for his replacement.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Doug Williamson, M.D., Executive Vice President, Head of Research and Development, will be leaving the company to pursue other opportunities. Dr. Williamson joined Acadia in January 2023 and will continue in his role during a transitional period. The company has initiated a search for his replacement.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231121667122/en/

Media Contact:

Acadia Pharmaceuticals Inc.

Deb Kazenelson

(818) 395-3043

media@acadia-pharm.com

Investor Contact:

Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.

Jessica Tieszen

(858) 261-2950

ir@acadia-pharm.com

Source: Acadia Pharmaceuticals Inc.

FAQ

Why is Dr. Doug Williamson leaving Acadia Pharmaceuticals Inc. (ACAD)?

Dr. Doug Williamson is leaving Acadia to pursue other opportunities.

When did Dr. Doug Williamson join Acadia Pharmaceuticals Inc. (ACAD)?

Dr. Doug Williamson joined Acadia in January 2023.

What is the role of Dr. Doug Williamson at Acadia Pharmaceuticals Inc. (ACAD)?

Dr. Doug Williamson is the Executive Vice President and Head of Research and Development at Acadia.

Is Acadia Pharmaceuticals Inc. (ACAD) looking for a replacement for Dr. Doug Williamson?

Yes, the company has initiated a search for his replacement.